Phase 1/2 Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma

Trial Profile

Phase 1/2 Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Glycopyranosyl lipid adjuvant (Primary) ; Pembrolizumab
  • Indications Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Immune Design
  • Most Recent Events

    • 12 Mar 2018 According to an Immune Design media release, results from this trial were presented at the American Society of Hematology Annual Meeting (ASH 2017).
    • 12 Mar 2018 Results published in an Immune Design media release.
    • 16 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top